{"id":41764,"date":"2025-09-18T12:19:49","date_gmt":"2025-09-18T04:19:49","guid":{"rendered":"https:\/\/flcube.com\/?p=41764"},"modified":"2025-09-18T12:19:50","modified_gmt":"2025-09-18T04:19:50","slug":"mabwell-bioscience-teams-with-aditum-bio-to-launch-kalexo-bio-inc-targeting-1-b-in-cardio-sirna-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41764","title":{"rendered":"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal"},"content":{"rendered":"\n<p><strong>Mabwell Bioscience (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>)<\/strong> announced a strategic partnership with <strong>Aditum Bio Fund\u202f3,\u202fL.P.<\/strong> to form <strong>Kalexo Bio,\u202fInc.<\/strong> The joint venture stems from a global exclusive licensing agreement for the dual\u2011target small\u2011interfering RNA (siRNA) asset <strong>2MW7141<\/strong>, a novel therapy in development for cardiovascular disease.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive rights<\/strong>: Mabwell transfers worldwide rights to develop, manufacture, and commercialise 2MW7141 to Kalexo.<\/li>\n\n\n\n<li><strong>Financial upside<\/strong>: Up to <strong>$1\u202fbillion<\/strong> in upfront and milestone payments, plus tiered royalties.<\/li>\n\n\n\n<li><strong>Immediate cash<\/strong>: A non\u2011refundable <strong>$12\u202fmillion<\/strong> payment is already in hand.<\/li>\n\n\n\n<li><strong>Equity component<\/strong>: Mabwell will receive an equity stake in Kalexo once key development milestones are achieved.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h4>\n\n\n\n<p>The partnership positions Kalexo to accelerate 2MW7141 from pre\u2011clinical to clinical stages while leveraging Mabwell\u2019s discovery platform and Aditum\u2019s deep\u2011capital resources. The siRNA\u2019s dual\u2011target design aims to modulate key inflammatory pathways implicated in atherosclerosis and heart failure, potentially filling a critical unmet need in cardiovascular therapeutics.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h4>\n\n\n\n<p>A $1\u202fbillion valuation framework signals robust investor confidence in siRNA therapeutics for non\u2011oncologic indications. If 2MW7141 demonstrates clinical efficacy, it could establish a new class of precision medicines for cardiovascular disease, prompting further investment in RNA\u2011based platforms across the biotech landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund\u202f3,\u202fL.P. to form Kalexo&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41766,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[69,4360,118,64,1129],"class_list":["post-41764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cvd","tag-kalexo-bio","tag-mabwell-bioscience","tag-rnai-aso","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund\u202f3,\u202fL.P. to form Kalexo\u202fBio,\u202fInc. The joint venture stems from a global exclusive licensing agreement for the dual\u2011target small\u2011interfering RNA (siRNA) asset 2MW7141, a novel therapy in development for cardiovascular disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41764\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal\" \/>\n<meta property=\"og:description\" content=\"Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund\u202f3,\u202fL.P. to form Kalexo\u202fBio,\u202fInc. The joint venture stems from a global exclusive licensing agreement for the dual\u2011target small\u2011interfering RNA (siRNA) asset 2MW7141, a novel therapy in development for cardiovascular disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41764\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-18T04:19:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-18T04:19:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal\",\"datePublished\":\"2025-09-18T04:19:49+00:00\",\"dateModified\":\"2025-09-18T04:19:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764\"},\"wordCount\":222,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1801.webp\",\"keywords\":[\"CVD\",\"Kalexo Bio\",\"Mabwell Bioscience\",\"RNAi \\\/ ASO\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41764#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41764\",\"name\":\"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1801.webp\",\"datePublished\":\"2025-09-18T04:19:49+00:00\",\"dateModified\":\"2025-09-18T04:19:50+00:00\",\"description\":\"Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund\u202f3,\u202fL.P. to form Kalexo\u202fBio,\u202fInc. The joint venture stems from a global exclusive licensing agreement for the dual\u2011target small\u2011interfering RNA (siRNA) asset 2MW7141, a novel therapy in development for cardiovascular disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41764\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41764#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund\u202f3,\u202fL.P. to form Kalexo\u202fBio,\u202fInc. The joint venture stems from a global exclusive licensing agreement for the dual\u2011target small\u2011interfering RNA (siRNA) asset 2MW7141, a novel therapy in development for cardiovascular disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41764","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal","og_description":"Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund\u202f3,\u202fL.P. to form Kalexo\u202fBio,\u202fInc. The joint venture stems from a global exclusive licensing agreement for the dual\u2011target small\u2011interfering RNA (siRNA) asset 2MW7141, a novel therapy in development for cardiovascular disease.","og_url":"https:\/\/flcube.com\/?p=41764","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-18T04:19:49+00:00","article_modified_time":"2025-09-18T04:19:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41764#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41764"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal","datePublished":"2025-09-18T04:19:49+00:00","dateModified":"2025-09-18T04:19:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41764"},"wordCount":222,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41764#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1801.webp","keywords":["CVD","Kalexo Bio","Mabwell Bioscience","RNAi \/ ASO","SHA: 688062"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41764#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41764","url":"https:\/\/flcube.com\/?p=41764","name":"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41764#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41764#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1801.webp","datePublished":"2025-09-18T04:19:49+00:00","dateModified":"2025-09-18T04:19:50+00:00","description":"Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund\u202f3,\u202fL.P. to form Kalexo\u202fBio,\u202fInc. The joint venture stems from a global exclusive licensing agreement for the dual\u2011target small\u2011interfering RNA (siRNA) asset 2MW7141, a novel therapy in development for cardiovascular disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41764#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41764"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41764#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1801.webp","width":1080,"height":608,"caption":"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41764#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1\u202fB in Cardio siRNA Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41764"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41764\/revisions"}],"predecessor-version":[{"id":41767,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41764\/revisions\/41767"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41766"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}